Every member of Eyevance’s leadership team has a background of experience in the ophthalmic space and shares a spirit of hard work, innovation, and drive to succeed. At Eyevance, we THINK, ACT, and DO differently.
Jerry St. Peter
Co-Founder, CEO and Director
Jerry St. Peter is the Co-Founder, Chief Executive Officer, and Director of Eyevance Pharmaceuticals. Since inception of the company in September 2017, Jerry manages and leads Eyevance’s business operations, communicates on behalf of the company, guides the development of Eyevance’s short, mid and long term strategies, and galvanizes the vision across the organization.
Jerry brings over 30 years of Ophthalmic executive leadership impacting strategic planning, commercial operations, financial management, business development, and overall general management. The hallmark and passion of his career is serving his customers – the doctors and colleagues he is loyal to.
Prior to co-founding Eyevance, Jerry was the Vice President and Head of Sun Pharmaceuticals’ newly formed Ophthalmics division. Previous to Sun, he was the Executive Vice President and General Manager for Nicox’s Ophthalmic business in the United States and formerly served as the Senior Vice President and Head of the Ophthalmic division at Inspire Pharmaceuticals.
What Jerry loves most about Eyevance is working alongside like-minded entrepreneurs who “choose the extraordinary” every day. His personal interests include enjoying timeless moments with his wife and best friend, Jamie, and inspiring his amazing children, Lylah, Beckham, and Sonoma. When time allows, Jerry finds being at the beach, golfing, or cheering on his beloved New England Patriots quite relaxing.
Co-Founder and COO
Jason Werner is the Co-Founder and Chief Operating Officer of Eyevance Pharmaceuticals. He co-founded Eyevance in September 2017 with Jerry St. Peter.
Jason oversees Technical Operations and Corporate Development & Licensing. Before co-founding Eyevance, he held roles of increasing responsibility in eye care, ranging from Sales, Product Development, Commercial Development, and Corporate Development & Licensing, while simultaneously executing more than 15 transactions totaling over $1 Billion over a five year span.
What Jason loves most about Eyevance is the people, hands down. His personal interests include family, travel, and all things Boston.
Chief Financial Officer
Wes Brazell is the Chief Financial Officer of Eyevance Pharmaceuticals. He’s been with Eyevance since April 2018. Wes is responsible for the company’s financial functions, including accounting, analysis, audit, treasury, and corporate finance. He is also responsible for overseeing the company’s compliance.
Wes has more than 25 years’ experience in ophthalmology, with varied experiences in financial management, business development, international operations, and corporate strategy.
His favorite thing about working for Eyevance is the energy and passion in creating something new, as well as the reward of seeing it grow and flourish. Wes is a history buff who enjoys music and water sports in his spare time.
Mark Jasek, PhD
Chief Scientific Officer
Mark C. Jasek, PhD is Eyevance’s Chief Scientific Officer. He’s been with Eyevance since February 2018. His responsibilities include Clinical Development, Medical Affairs, and Regulatory Affairs.
Dr. Jasek has spent 21 years in the ophthalmic space with global experience spanning from bench science, Clinical Development, Pharmacokinetics, Medical Affairs, Sales Training, Advocate Development, Marketing, Business Development, and Executive Leadership.
Dr. Jasek’s favorite thing about working at Eyevance is the opportunity to develop what he calls “the most exciting therapeutic I have ever been involved with in my career.” He’s also grateful for the incredible people he gets to work with on a daily basis. Dr. Jasek’s personal interests include family, travel, hiking, fishing, and scuba diving.
Chief Commercial Officer
Julie Speed is the Chief Commercial Officer and Eyevance’s newest team member. Her responsibilities at Eyevance include developing the go-forward commercial strategy and overseeing the growth of Eyevance’s product portfolio.
Julie has over 21 years of proven ophthalmic experience, including deep expertise in the ocular surface and anterior segment subspecialties. She joined the Eyevance team due to the robust product pipeline of commercial and development stage products to address many unmet ophthalmic market needs. She strongly believes Eyevance is well positioned for success in 2020 and beyond.
Julie’s personal interests include traveling with her family, including outdoor camping adventures.
Jodi Luchs, MD
Co-Chief Medical Officer
Dr. Luchs graduated from the University of Pennsylvania in 1987 and received his Doctor of Medicine degree in 1991 from the Albert Einstein College of Medicine in New York. He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center. He then completed a fellowship in Cornea/External Disease at the prestigious Wills Eye Hospital in Philadelphia. Following his training, Dr. Luchs joined South Shore Eye Care in 1996 as their Director of Clinical Research and Director of Cornea/External Diseases and Refractive Surgery. He served as the Co-Director of the Division of Refractive Surgery for the Long Island Jewish/North Shore University Health System from 2006- 2016. Dr. Luchs is an Associate Clinical Professor of Ophthalmology at Hofstra Northwell School of Medicine and was named the Managing Director of the Garden City SurgiCenter of Northwell Health. In 2018, Dr. Luchs Joined Florida Vision Institute in West Palm Beach, Florida.
He has numerous publications on cornea, external diseases, and refractive surgery to his credit, including two books, and has lectured nationally and internationally. He has been the Principal Investigator for over 100 clinical trials, including those which led to the approval of many ophthalmic medications and devices used today.
Dr. Luchs is board certified by the American Board of Ophthalmology and a Fellow of the American Academy of Ophthalmology, the American College of Surgeons, and the American Society of Cataract and Refractive Surgery (ASCRS). He is also a member of the Castroviejo Corneal Society, the International Society of Refractive Surgery, the Refractive Surgery Alliance, and a founding member of both the American-European Congress of Ophthalmic Surgery (AECOS) and the Society of Cornea, External Disease and Refractive Surgeons (CEDARS).
He serves as an Assistant Editor for Advanced Ocular Care, Therapeutics/ Cornea & External Disease section, an Assistant Editor for Ocular Surgery News, Technology Section, and an Editor of the American Academy of Ophthalmology’s Ophthalmic News and Education (O.N.E.) network, Cataract Section.
In 2015, he received the American Academy of Ophthalmology’s Achievement award. In 2016, he was named to the Ocular Surgery News Premier Surgeon 300 Innovators in Refractive Cataract Surgery list.
In 2017, Dr. Luchs became the Chief Science Advisor for InFocus Capital Partners, a private venture capital firm dedicated to investing in companies developing promising new Ophthalmic medications and devices.
In 2017, he also became the Co-Chief Medical Officer of Eyevance Pharmaceuticals as well as the Co-Founder of Evolve Ophthalmics.
Mark S. Milner, MD
Co-Chief Medical Officer
Mark S. Milner, M.D. is a board-certified ophthalmologist and a fellowship-trained corneal surgeon. Dr. Milner received his Bachelor of Science degree from Union College and his Doctor of Medicine degree from the State University of New York Health Science Center, Syracuse, NY. He interned in internal medicine at Robert Wood Johnson University Hospital, New Brunswick, NJ, and completed his residency in ophthalmology at the New York Eye and Ear Infirmary. His fellowship in cornea, external disease and uveitis was completed at the prestigious Francis I. Proctor Foundation at the University of California, San Francisco.
Dr. Milner is an Associate Clinical Professor at Yale University Medical School, Department of Ophthalmology. He was both a Co-Founder and Co-Medical Director of Precision LASIK Group, Cheshire, CT. He previously held the positions of Director of the Cornea Clinic at the Veterans Administration Medical Center in West Haven, CT, and the Medical Director of Education for Sunrise Technologies.
Dr. Milner is actively involved in research. He has been the Principle Investigator for several clinical studies and has authored various publications, including a 44 page peer reviewed article in Current Opinion in Ophthalmology (January 2017) detailing his innovative algorithm and approach to the diagnosis and treatment of dry eye disease. He was awarded with the Yale Department of Ophthalmology Teaching Award for “Excellence in Teaching” in 1998 and was voted a “Top Doctor” in 2009, 2010, 2011, 2012, 2013, 2014 and 2015 in Connecticut Magazine by his peers. In 2016 he was selected on the list of Ocular Surgery News (OSN) Premier Surgeon 300 as one of the top 300 premier surgeons and leading innovators in the U.S. in the field of refractive cataract surgery.
Dr. Milner specializes in cornea, external diseases, refractive surgery, and uveitis, with a focused interest in dry eye disease and dysfunctional tear syndrome. He has built a large dry eye practice and has lectured throughout the world teaching other physicians about dysfunctional tear syndrome and his innovative approach, algorithm, and treatments.
Dr. Milner is a Fellow of the American College of Surgeons and a member of the American Board of Ophthalmology, the American Medical Association, the International Society of Refractive Surgery, the American Society of Cataract and Refractive Surgery, the Connecticut Society of Eye Physicians, the New Haven County Medical Society, and is a founding member of The CEDARS/ASPENS Society.